{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:51Z","timestamp":1788419871067,"version":"build-2803163510"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341206"],"award-info":[{"award-number":["82341206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130004"],"award-info":[{"award-number":["82130004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82561160165"],"award-info":[{"award-number":["82561160165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFF0500705"],"award-info":[{"award-number":["2025YFF0500705"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019540","name":"Science Fund for Distinguished Young Scholars of Zhejiang Province","doi-asserted-by":"publisher","award":["LR26H080001"],"award-info":[{"award-number":["LR26H080001"]}],"id":[{"id":"10.13039\/501100019540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>CD7 is a promising target for chimeric antigen receptor (CAR) T-cell therapy in T-cell lymphoid malignancies; however, antigen loss\u2013mediated relapse has emerged as a major challenge. In this study, we systematically analyzed the genetic and epigenetic alterations of paired specimens (pretreatment and relapsed) from 10 patients with T-cell lymphoma\/leukemia receiving CD7 CAR T cells. Overall, we identified three distinct mechanisms underlying CD7 loss: first, frameshift insertion (patient 4; c.164dupG:p.R55fs) or deletion (patient 7; c.122delG:p.G41Efs*19) resulting in truncation of the CD7 transmembrane domain in two of 10 patients; second, hypermethylation of the CD7 promoter in seven of 10 patients without CD7 mutation; third, simultaneous occurrence of promoter region hypermethylation and multiple in-frame mutations with predicted functional interference in one of 10 patients (patient 2). Collectively, these findings demonstrate that both clonal heterogeneity and epigenetic plasticity drive antigen-negative relapse in T-cell lymphoid malignancies under the selective pressure of CD7 CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Understanding mechanisms of antigen-negative relapse is critical for developing effective CD7-targeting CAR-T therapies against T-cell lymphoid malignancies. Our study identifies both genetic truncation mutations and epigenetic silencing as contributors to CD7-negative relapse. Monitoring and preventing these events is warranted to improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0489","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:39:13Z","timestamp":1783539553000},"page":"687-696","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T\u2013Treated T-cell Lymphoid Malignancies"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2539-8286","authenticated-orcid":false,"given":"Rongrong","family":"Chen","sequence":"first","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9747-948X","authenticated-orcid":false,"given":"Haiqiong","family":"Zheng","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7537-440X","authenticated-orcid":false,"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4964-8513","authenticated-orcid":false,"given":"Shan","family":"Fu","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7758-0784","authenticated-orcid":false,"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-4499","authenticated-orcid":false,"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-309X","authenticated-orcid":false,"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[{"name":"4Shanghai YaKe Biotechnology Ltd., Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-462X","authenticated-orcid":false,"given":"Jiangtao","family":"Ren","sequence":"additional","affiliation":[{"name":"5Bioheng Therapeutics Co., Ltd., Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9619-2614","authenticated-orcid":false,"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China."},{"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"publisher"}],"name":"Zhejiang University 2 Institute of Hematology, , Hangzhou, China."},{"name":"3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026090303073733500_bib1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"2026090303073733500_bib2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","article-title":"Relapsed T cell ALL: current approaches and new directions","volume":"14","author":"McMahon","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"2026090303073733500_bib3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","article-title":"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia","volume":"6","author":"Xu","year":"2025","journal-title":"Nat Cancer"},{"key":"2026090303073733500_bib4","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1073\/pnas.76.11.5829","article-title":"Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets","volume":"76","author":"Haynes","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090303073733500_bib5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J Immunol"},{"key":"2026090303073733500_bib6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood.v77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"2026090303073733500_bib7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"2026090303073733500_bib8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"2026090303073733500_bib9","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090303073733500_bib10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026090303073733500_bib11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","article-title":"Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: a phase I trial","volume":"33","author":"Zhao","year":"2025","journal-title":"Mol Ther"},{"key":"2026090303073733500_bib12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090303073733500_bib13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303073733500_bib14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090303073733500_bib15","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"2026090303073733500_bib16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090303073733500_bib17","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2026090303073733500_bib18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090303073733500_bib19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"2026090303073733500_bib20","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"key":"2026090303073733500_bib21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2026090303073733500_bib22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2026090303073733500_bib23","doi-asserted-by":"publisher","first-page":"e002352","DOI":"10.1136\/jitc-2021-002352","article-title":"Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro","volume":"9","author":"Ledererova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090303073733500_bib24","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2026090303073733500_bib25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"2026090303073733500_bib26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"2026090303073733500_bib27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"2026090303073733500_bib28","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2026090303073733500_bib29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-4598-9-41","article-title":"Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia","volume":"9","author":"Rogers","year":"2010","journal-title":"Mol Cancer"},{"key":"2026090303073733500_bib30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/ijmm.2011.756","article-title":"Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia\/lymphoma","volume":"28","author":"Uenogawa","year":"2011","journal-title":"Int J Mol Med"},{"key":"2026090303073733500_bib31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood-2005-09-3765","article-title":"Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma","volume":"107","author":"Ushmorov","year":"2006","journal-title":"Blood"},{"key":"2026090303073733500_bib32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-3-15","article-title":"CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation","volume":"3","author":"R\u00f6hrs","year":"2010","journal-title":"J Hematol Oncol"},{"key":"2026090303073733500_bib33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1042\/bst20200695","article-title":"Sequence determinants, function, and evolution of CpG islands","volume":"49","author":"Angeloni","year":"2021","journal-title":"Biochem Soc Trans"},{"key":"2026090303073733500_bib34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.stem.2014.06.018","article-title":"Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells","volume":"15","author":"Challen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2026090303073733500_bib35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2024026622","article-title":"Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"2026090303073733500_bib36","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1016\/j.molcel.2021.07.031","article-title":"Structure of the human signal peptidase complex reveals the determinants for signal peptide cleavage","volume":"81","author":"Liaci","year":"2021","journal-title":"Mol Cell"},{"key":"2026090303073733500_bib37","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.3324\/haematol.2023.283566","article-title":"Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed\/refractory T-cell acute lymphoblastic leukemia","volume":"108","author":"Aldoss","year":"2023","journal-title":"Haematologica"},{"key":"2026090303073733500_bib38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"2026090303073733500_bib39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0022-2836(87)90689-9","article-title":"CpG islands in vertebrate genomes","volume":"196","author":"Gardiner-Garden","year":"1987","journal-title":"J Mol Biol"},{"key":"2026090303073733500_bib40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41592-020-01041-y","article-title":"High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing","volume":"18","author":"Karst","year":"2021","journal-title":"Nat Methods"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0489\/3810810\/bcd-25-0489.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0489\/3821472\/bcd-25-0489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/687\/3824882\/bcd-25-0489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/687\/3824882\/bcd-25-0489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:07:45Z","timestamp":1788419265000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/687\/787645\/Genetic-Mutation-and-Epigenetic-Silencing-Drive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0489","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}